Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADPT Adaptive Biotechnologies Corp

Pre-Mkt 06-26 08:11:57 EDT

20.25

+0.91

+4.71%

盘前20.25

+0.000.00%

08:08 EDT

High20.64	Low19.53	Vol3.96M
Open19.61	D1 Closing19.34	Amplitude5.74%
Mkt Cap3.24B	Tradable Cap2.38B	Total Shares159.76M
T/O79.70M	T/O Rate3.38%	Tradable Shares117.37M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADPT","market":"US","secType":"STK","nameCN":"Adaptive Biotechnologies Corp","latestPrice":20.25,"timestamp":1782417600000,"preClose":19.34,"halted":0,"volume":3961781,"hourTrading":{"tag":"盘前","latestPrice":20.25,"preClose":20.25,"latestTime":"08:08 EDT","volume":353,"amount":7175.232260999999,"timestamp":1782475689232,"change":0,"changeRate":0,"amplitude":0.042454},"delay":0,"changeRate":0.047052740434332996,"floatShares":117369033,"shares":159760700,"eps":-0.325352,"marketStatus":"Pre-Mkt","change":0.91,"latestTime":"06-26 08:11:57 EDT","open":19.605,"high":20.64,"low":19.53,"amount":79700321.064176,"amplitude":0.057394,"askPrice":20.25,"askSize":100,"bidPrice":20.05,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-0.325352,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1782480600000},"marketStatusCode":1,"adr":0,"listingDate":1561608000000,"exchange":"NASDAQ","adjPreClose":20.25,"preHourTrading":{"tag":"盘前","latestPrice":20.25,"preClose":20.25,"latestTime":"08:08 EDT","volume":353,"amount":7175.232260999999,"timestamp":1782475689232,"change":0,"changeRate":0,"amplitude":0.042454},"postHourTrading":{"tag":"盘后","latestPrice":20.26,"preClose":20.25,"latestTime":"19:42 EDT","volume":125993,"amount":2551513.9682,"timestamp":1782430928717,"change":0.01,"changeRate":0.000494,"amplitude":0.018765},"volumeRatio":0.7213930801030219,"impliedVol":0.8015,"impliedVolPercentile":0.472},"requestUrl":"/m/hq/s/ADPT/tweets","defaultTab":"tweets","newsList":[{"id":"2645008400","title":"Adaptive Biotechnologies Issues $345 Million Convertible Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2645008400","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645008400?lang=en_us&edition=fundamental","pubTime":"2026-06-23 05:38","pubTimestamp":1782164337,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies  said late Monday it has issued $345 million of 0% convertible senior notes due 2031, including the full exercise of an over-allotment option.Net proceeds were used among others for capped call transactions, share repurchase, and for the repayment of the OrbiMed purchase agreement, the company said in a filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645774300","title":"Adaptive Biotechnologies Corp - Issues $345 Mln in 0% Convertible Senior Notes Due 2031 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2645774300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645774300?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:08","pubTimestamp":1782158918,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42U0LK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645077439","title":"Adaptive Biotechnologies prices upsized USD 300 million 0% convertible senior notes offering due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2645077439","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645077439?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:07","pubTimestamp":1782158878,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies priced an upsized private offering of USD 300 million 0% convertible senior notes due 2031, raised from USD 250 million.Settlement is scheduled for June 22, 2026; initial purchasers hold an option to buy up to an additional USD 45 million of notes.Net proceeds estimated at about USD 290.8 million, or about USD 334.5 million if the option is fully exercised.Proceeds earmarked to repay the OrbiMed Purchase Agreement, fund a capped call, repurchase USD 25 million of stock, support MRD initiatives.Initial conversion price set at about USD 24.11 per share; capped call cap price set at USD 34.44.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLbwQ5DJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644720722","title":"Adaptive Biotechnologies CSO Harlan S. Robins sells 106,160 shares for $1.85 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644720722","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644720722?lang=en_us&edition=fundamental","pubTime":"2026-06-18 08:11","pubTimestamp":1781741513,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Chief Scientific Officer Harlan S. Robins sold 106,160 common shares on June 15-16.Sales priced at $17.37, $18.01; holdings fell to 1,405,898 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDLbQYYnq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies CSO Harlan S. Robins sells 106,160 shares for $1.85 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644751747","title":"BUZZ-U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron","url":"https://stock-news.laohu8.com/highlight/detail?id=2644751747","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644751747?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:42","pubTimestamp":1781710974,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, MicronWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nL6N42P12K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MUU","INLF","EHGO","LINT","SKIL","HOOI","HOOY","PTRN","QURE","TXG","GNK","TGE","DSX","ADTX","SATG","ECHO","SHAZ","LRCX","VSTM","HOOX","AMAT","KMX","MU","LRCU","ADPT","CME","WBX","INTW","HOOD","INTC","ICCM","CVNA","JBL","ASTS","LZB","SATS","SOPH","CVNX","LDOS","SNBRQ","ASTN","BIRD","NEO","ASTX","SNBR","SVAQ","FTHM","KLAC","BWXT","WDC","WNC","KLAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644474097","title":"Adaptive Biotechnologies Price Target Maintained With a $22.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2644474097","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644474097?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:32","pubTimestamp":1781710320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADPT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2026 11:32 ET (15:32 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745054","title":"Adaptive Biotechnologies prices $300M convertible senior note offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745054","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644745054?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:11","pubTimestamp":1781698290,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies (ADPT) “announced the pricing of its offering of $300 million aggregate principal amount of 0% convertible senior notes du...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-prices-300m-convertible-senior-note-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-prices-300m-convertible-senior-note-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644498743","title":"BUZZ-U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, AST SpaceMobile","url":"https://stock-news.laohu8.com/highlight/detail?id=2644498743","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644498743?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:35","pubTimestamp":1781696109,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, AST SpaceMobileWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslette","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nL6N42P0SY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASTN","BK4543","LU2931357623.SGD","ASTX","BK4554","LINT","BK4575","LU2543165471.USD","LZB","BK4588","BK4123","LU0097036916.USD","ADPT","LU2357627491.SGD","INTC","BK4605","LU2764263039.SGD","IE000M9KFDE8.USD","LU2764262908.HKD","04335","BK4615","LU2148611432.USD","LU2720916845.USD","HK0000304797.USD","INTW","BK4579","BK4516","ASTS","BK4512","BK4533","BK4534","BK4214","BK4095","BK4089","HK0000304805.HKD","LU0149725797.USD","LU2089985449.USD","BK4585","LDOS","LU0274383776.USD","LU0859254822.USD","LU0082616367.USD","BK4527","KMX","BK4515","LU0081259029.USD","BK4529","LU0719512351.SGD","LU2764263203.CNY","LU0321505439.SGD","BK4121","LU0006061336.USD","LU0321505868.SGD","IE0009354923.USD","BK4535","BK4602","BK4612","LU0154236417.USD","BK4550","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644438587","title":"BUZZ-Adaptive Biotechnologies up after boosted $300 mln convertible bond sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2644438587","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644438587?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:18","pubTimestamp":1781695107,"startTime":"0","endTime":"0","summary":"BUZZ-Adaptive Biotechnologies up after boosted $300 mln convertible bond sale** Shares of Adaptive Biotechnologies ADPT.O up 0.5% at $17.30 before the bell on Weds as co raises more capital than planned** Seattle, Washington-based ADPT announces pricing private offering of $300 mln 0% convertible bonds due 2031** Offering size increased from $250 mln; initial conversion price of $24.11 is 40% premium to stock's last sale of $17.22 on Tues** Co intends to use net offering proceeds to repay OrbiMed purchase agreement, for general purposes and opportunistic initiatives in Minimal Residual Disease  business** Late Mon, ADPT unveiled plans to separate its MRD and Immune Medicine businesses, with CEO and co-founder Chad Robins saying it's \"the best way to unlock the full potential of both businesses, increasing their impact on patients and creating long-term value for shareholders\"** ADPT stock closed down 1.4% on Tues for about $2.8 bln market cap. Stock up 6% YTD and 67% over the past 12 m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nL6N42P0RI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BUZZ-Adaptive Biotechnologies up after boosted $300 mln convertible bond sale","news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644411717","title":"Adaptive Biotechnologies prices upsized USD 300 million 0% convertible senior notes offering due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2644411717","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644411717?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:00","pubTimestamp":1781690450,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies priced an upsized USD 300 million private offering of 0% convertible senior notes due 2031, raised from USD 250 million.Deal includes a 13-day option for initial purchasers to buy up to an additional USD 45 million of notes.Net proceeds estimated at USD 290.8 million, rising to about USD 334.5 million if the option is fully exercised.Proceeds earmarked to repay the OrbiMed Purchase Agreement, fund a USD 22.3 million capped call, repurchase USD 25 million of stock.Notes convert at 41.48 shares per USD 1,000, implying a USD 24.11 conversion price; settlement scheduled for June 22, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL8JKdhl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014005.SGD","LU0314104364.USD","BK4121","BK4112","BK4588","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","ADPT","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","BK4585","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644174587","title":"Adaptive Biotechnologies - Prices $300 Mln 0% Convertible Senior Notes Due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2644174587","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644174587?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:00","pubTimestamp":1781690400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUA8QYY0J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644717757","title":"Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2644717757","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644717757?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:00","pubTimestamp":1781690400,"startTime":"0","endTime":"0","summary":"Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibilityAdditional proceeds used to pay for the capped call with a premium of 100% and to repurchase $2","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/17/3313253/0/en/Adaptive-Biotechnologies-Corporation-Prices-Upsized-300-Million-Convertible-Senior-Notes-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644715644","title":"MRD Spinoff And $250 Million Convertible Notes Could Be A Game Changer For Adaptive Biotechnologies (ADPT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644715644","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644715644?lang=en_us&edition=fundamental","pubTime":"2026-06-17 14:25","pubTimestamp":1781677527,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies recently completed a US$250,000,000 private offering of unsecured, senior, callable convertible notes due July 1, 2031, while also outlining plans to separate its profitable Minimal Residual Disease (MRD) unit from its Immune Medicine business.\nThe combination of business separation and new convertible debt signals a meaningful reshaping of Adaptive’s capital structure and business focus, with MRD positioned as the primary engine and Immune Medicine seeking growth...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/mrd-spinoff-and-250-million-convertible-notes-could-be-a-gam","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/mrd-spinoff-and-250-million-convertible-notes-could-be-a-gam","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADPT","BK7095","MRD.AU","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644766759","title":"Analysts Are Bullish on Top Healthcare Stocks: Pasithea Therapeutics Corp (KTTA), Adaptive Biotechnologies (ADPT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644766759","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644766759?lang=en_us&edition=fundamental","pubTime":"2026-06-16 23:50","pubTimestamp":1781625010,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pasithea Therapeutics Corp (KTTA) and Adaptive Biote...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-pasithea-therapeutics-corp-ktta-adaptive-biotechnologies-adpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-pasithea-therapeutics-corp-ktta-adaptive-biotechnologies-adpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4121","KTTA","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643875264","title":"Adaptive Biotechnologies offers to sell $250M in 2031 convertible senior notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2643875264","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643875264?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:18","pubTimestamp":1781612288,"startTime":"0","endTime":"0","summary":"Last night, the company stated: “Adaptive Biotechnologies (ADPT) announced its intention to offer, subject to market and other conditions, $250 mil...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-offers-to-sell-250m-in-2031-convertible-senior-notes-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-offers-to-sell-250m-in-2031-convertible-senior-notes-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643817587","title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky disposes of 5,000 common shares for $95,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2643817587","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643817587?lang=en_us&edition=fundamental","pubTime":"2026-06-16 07:13","pubTimestamp":1781565223,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Chief Commercial Officer, MRD Susan Bobulsky sold 5,000 common shares on June 11, 2026 at USD 19.Directly held stake fell to 411,775 shares following the transaction.Sale was executed under a Rule 10b5-1 trading plan adopted on Dec. 16, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 15, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL4Wr9Jv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky disposes of 5,000 common shares for $95,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643811187","title":"Stocks to Watch: Dave & Buster's, Adaptive Biotechnologies, Domo, Apollo Commercial Real Estate Finance","url":"https://stock-news.laohu8.com/highlight/detail?id=2643811187","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643811187?lang=en_us&edition=fundamental","pubTime":"2026-06-16 06:52","pubTimestamp":1781563920,"startTime":"0","endTime":"0","summary":"Dave & Buster's Entertainment reported a lower profit as revenue and comparable store sales declined in the first quarter. The stock slid 12% to $10.90 in after-hours trading on Monday.Adaptive Biotechnologies said it is mulling strategic alternatives for its immune medicine unit. Shares fell 6.8% to $16.27 after the bell.Domo issued a going concern warning, and said it lacks the resources to repay its debts. The company said it is nearing a possible strategic transaction. The stock was down 4.9% to $3.10.Apollo Commercial Real Estate Finance said it would dissolve the company, liquidate its assets, and distribute a special dividend of $3.75 a share. Shares rose 2.5% to $10.93.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4216","BK4209","DOMO","ARI","BK4110","BK4023","BK4121","PLAY","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643781990","title":"BRIEF-Adaptive Biotechnologies Announces Proposed Convertible Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2643781990","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643781990?lang=en_us&edition=fundamental","pubTime":"2026-06-16 06:47","pubTimestamp":1781563667,"startTime":"0","endTime":"0","summary":"BRIEF-Adaptive Biotechnologies Announces Proposed Convertible Senior Notes OfferingJune 15 (Reuters) - Adaptive Biotechnologies Corp ADPT.O:ADAPTIVE BIOTECHNOLOGIES CORPORATION ANNOUNCES PROPOSED CONV","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUABLYQKP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643869017","title":"Adaptive Biotechnologies Evaluates Strategic Alternatives for Immune Medicine Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2643869017","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643869017?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:50","pubTimestamp":1781556600,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies is evaluating strategic alternatives for its immune medicine unit as it plans to separate the business from its minimal residual disease arm.The company said Monday it is looking at alternatives for its immune medicine business to support its growth and capital needs, and expects to decide on a path to separation by the end of the year.Adaptive established its immune medicine and minimal residual disease businesses as separate operating segments in 2024. In the time since, immune medicine has increasingly demonstrated its potential to generate novel biological insights, identify therapeutic targets and accelerate the development of precision medicines, and Adaptive now sees it benefiting outside of a diagnostic commercial model.\"As we look ahead, Adaptive will focus on expanding its leadership in MRD diagnostics, while pursuing the optimal path for Immune Medicine outside of Adaptive,\" Chief Executive Chad Robins said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643978650","title":"Adaptive Biotechnologies Weighs Separation of Immune Medicine Unit; Shares Fall After Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2643978650","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643978650?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:43","pubTimestamp":1781556199,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies  is evaluating strategic and structural alternatives for its immune medicine segment in a plan to separate the business from its minimal residual disease division.A decision on the separation is expected by year-end, the company said Monday in a statement.Adaptive shares fell 5.6% in after-hours trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.adaptivebiotech.com","stockEarnings":[{"period":"1week","weight":0.1552},{"period":"1month","weight":0.4331},{"period":"3month","weight":0.6317},{"period":"6month","weight":0.2126},{"period":"1year","weight":0.6903},{"period":"ytd","weight":0.2469}],"compareEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":-0.0217},{"period":"3month","weight":0.158},{"period":"6month","weight":0.0637},{"period":"1year","weight":0.2095},{"period":"ytd","weight":0.0768}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.006662},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.034164},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.108302},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.084119},{"month":5,"riseRate":0.571429,"avgChangeRate":0.103614},{"month":6,"riseRate":0.857143,"avgChangeRate":0.13415},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.001043},{"month":8,"riseRate":0.571429,"avgChangeRate":0.074393},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.065733},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.030408},{"month":11,"riseRate":0.714286,"avgChangeRate":0.049327},{"month":12,"riseRate":0.714286,"avgChangeRate":0.032336}],"exchange":"NASDAQ","name":"Adaptive Biotechnologies Corp","nameEN":"Adaptive Biotechnologies Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adaptive Biotechnologies Corp(ADPT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adaptive Biotechnologies Corp,ADPT,Adaptive Biotechnologies Corp股票,Adaptive Biotechnologies Corp股票老虎,Adaptive Biotechnologies Corp股票老虎国际,Adaptive Biotechnologies Corp行情,Adaptive Biotechnologies Corp股票行情,Adaptive Biotechnologies Corp股价,Adaptive Biotechnologies Corp股市,Adaptive Biotechnologies Corp股票价格,Adaptive Biotechnologies Corp股票交易,Adaptive Biotechnologies Corp股票购买,Adaptive Biotechnologies Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adaptive Biotechnologies Corp(ADPT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}